DelveInsight's 'Endometriosis Pipeline Insight 2025' report provides comprehensive global coverage of pipeline endometriosis ...

A pathway once considered fundamental in Alzheimer’s disease is being studied intensely again, and may soon result in safer, ...

As per the Brain and Behavior Research Foundation, it combines two compounds called xanomeline and trospium chloride. This is ...

Anavex’s newest patent will be expected to remain in force at least until July 2039, not including any patent term extensions. It will expand and supplement the current ANAVEX®2-73 (blarcamesine) ...

导言精神疾病领域的研究在2024年取得了令人瞩目的进展，不仅在创新药物的研发和适应症扩展方面不断突破，也在发病机制和生物学基础等基础研究层面深入拓展，为精神疾病的诊疗与预后带来了新的可能性。特别是在精神分裂症、双相情感障碍以及阿尔茨海默症等重大精神和 ...

Xanomeline and trospium chloride (KarXT), a novel M1/M4 muscarinic receptor agonist, significantly improves cognitive ...

It is administered through oral route as tablets and through intravenous route. It acts by targeting Muscarinic Acetylcholine Receptor M1 (CHRM1). It was also under development for the treatment of ...

Copyright: © 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

A Vanderbilt University patent discloses new muscarinic M4 receptor positive allosteric modulators and agonists reported to be useful for the treatment of Alzheimer’s disease, pain, schizophrenia, ...

For instance, cobenfy is the first new schizophrenia drug approved in nearly three decades. Developed by Karuna Therapeutics and later acquired by Bristol Myers Squibb, it targets the cholinergic ...

The medications inside inhalers work in different ways and are prescribed for various reasons. Combination meds with an ICS and LABA option to relax and open airways, like Advair (fluticasone with ...

Nxera and Neurocrine entered a collaboration and licensing agreement in 2021 to develop a portfolio of novel clinical and preclinical subtype-selective muscarinic M4, M1 and dual M1/M4 receptor ...